LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "multi selective" as a keyword



Abstract 5512: Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven byKRASG12C amplification or NRASG13R mutation

Sign Up to like & get
recommendations! Published in 2025 at "Cancer Research"

DOI: 10.1158/1538-7445.am2025-5512

Abstract: Amplification of the KRASG12C mutant allele and acquisition of NRAS mutations have been reported as resistance mechanisms in tumors progressing on sotorasib and adagrasib. We also identified these alterations in resistance models generated in vitro… read more here.

Keywords: ras multi; resistance; combination; rmc ... See more keywords

Abstract 6405: T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC

Sign Up to like & get
recommendations! Published in 2025 at "Cancer Research"

DOI: 10.1158/1538-7445.am2025-6405

Abstract: Activating mutations in KRAS drive tumorigenesis in more than 90% of cases of pancreatic ductal adenocarcinoma (PDAC), promoting tumor cell proliferation and survival and contributing to an immunosuppressive tumor microenvironment (TME). RAS(ON) multi-selective inhibitors, such… read more here.

Keywords: ras multi; tumor regressions; tumor; multi selective ... See more keywords

Abstract LB281: Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies

Sign Up to like & get
recommendations! Published in 2025 at "Cancer Research"

DOI: 10.1158/1538-7445.am2025-lb281

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is driven by oncogenic RAS mutations in >90% of cases. Daraxonrasib (RMC-6236) is an orally bioavailable RAS(ON) multi-selective tri-complex inhibitor with broad-spectrum activity against oncogenic mutant… read more here.

Keywords: ras multi; resistance; daraxonrasib; multi selective ... See more keywords

RAS(ON) multi-selective inhibition drives antitumor immunity in preclinical models of NRAS-mutant melanoma.

Sign Up to like & get
recommendations! Published in 2025 at "Cancer immunology research"

DOI: 10.1158/2326-6066.cir-25-0744

Abstract: Targeted therapies for NRAS-mutant melanoma remain an unmet clinical need. Here, we demonstrate that RMC-7977, a preclinical RAS(ON) multi-selective inhibitor representative of the investigational agent daraxonrasib (RMC-6236), was able to elicit potent antitumor immune responses… read more here.

Keywords: ras multi; nras mutant; rmc; multi selective ... See more keywords